Evidence map›Paper›PMID 36678764›Full record

ArticlePharmaceutics2022

Antioxidant and Cytotoxic Activity of New Polyphenolic Derivatives of Quinazolin-4(3H)-one: Synthesis and In Vitro Activities Evaluation.

Raluca Pele, Gabriel Marc, Ioana Ionuț, Cristina Nastasă, Ionel Fizeșan, Adrian Pîrnău, Laurian Vlase, Mariana Palage, Smaranda Oniga, Ovidiu Oniga

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. RHA/TiOScientific reports · 2026
    Article
  2. New Quinazolin-4(3Molecules (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Raluca PeleDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Gabriel MarcDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0001-9397-0388
Ioana IonuțDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Cristina NastasăDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-5803-6108
Ionel FizeșanDepartment of Toxicology, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8 Victor Babeș, 400012 Cluj-Napoca, Romania.
Adrian PîrnăuNational Institute for Research and Development of Isotopic and Molecular Technologies, 400293 Cluj-Napoca, Romania.
Laurian VlaseDepartment of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-0664-3387
Mariana PalageDepartment of Therapeutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 12 Ion Creangă, 400010 Cluj-Napoca, Romania.ORCID 0000-0002-9943-1083
Smaranda OnigaDepartment of Therapeutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 12 Ion Creangă, 400010 Cluj-Napoca, Romania.ORCID 0000-0002-0297-7697
Ovidiu OnigaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Iuliu Hațieganu University of Medicine and Pharmacy · RONational Institute for Research and Development of Isotopic and Molecular Technologies · RO

Funding

"Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania PCD 1033/50/13.01.2021"Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania PCD 2461/54/17.01.2020Romanian Ministry of Research and Innovation PN-III-P2-2.1-PTE-2021-0303
6 · The paper itself

Abstract

The development of hybrid molecules with significant human therapeutic properties is one of the main approaches of pharmaceutical research. One of the most important pharmacophores is the quinazolin-4(3H)-one heterocycle moiety, due to its wide range of biological activities. By its derivatization with polyphenolic compounds, in our previous research, it proved to possess a good antiradical activity of

Indexed as

antioxidantcytotoxichybrid moleculesin vitro evaluationphenolic derivativesquinazolin-4(3H)-one

Identifiers

PMID36678764
PMCPMC9867241
OpenAlexW4313472514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.